<b>stem cell</b>Madison stem cell firm Cellular Dynamics International Inc. said Wednesday it has licensed a pair of patents that will advance its effort to mass produce stem cell-derived cells for pharmaceutical companies.

Cellular Dynamics, a firm founded by stem cell pioneer James Thomson of the University of Wisconsin-Madison, has exclusively licensed a U.S.-issued patent portfolio on optimizing the stem cell differentiation selection process and on using heart cells in drug testing. The licenses were obtained from Indiana University-Purdue University Indianapolis (IUPUI) and its researcher Dr. Loren Field.

Terms of the license were not disclosed.

Cellular Dynamics is using the technology in conjunction with the patents it has licensed from the Wisconsin Alumni Research Foundation, UW-Madison’s tech-transfer vehicle, to create a pipeline that mass produces cells for large-scale drug screening campaigns at pharmaceutical companies and for regenerative medicine applications.

In addition, the license, which includes patents pending at the European Patent Office, also allows CDI to sublicense to other companies and institutions.

Cellular Dynamics International is a developer of next-generation stem cell technologies for drug development and personalized medicine applications. It recently announced that it was able to generate pluripotent stem cells, which have the ability to generate all tissue types in the body, from small volumes of human blood samples.

The firm said the advance represented a major step toward large-scale processing and industrialization of stem cells. The people are also waiting for the day when stem cells would be available at a much affordable price, and it is only possible if productivity at commercial level is achieved.

Source: The Business Journal